Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Pioglitazone Hydrochloride Tablet 45mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Actos® (Pioglitazone Hydrochloride) Tablet 45mg [Reference Formulation, Takeda Pharmaceuticals America, Inc.] in Healthy Human Volunteers Under Fed Conditions.

NCT01798940 is registered in ClinicalTrials.gov with Torrent Pharmaceuticals Limited as lead sponsor.

NCT NCT01798940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01798940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Pioglitazone Hydrochloride Tablet 45mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Actos® (Pioglitazone Hydrochloride) Tablet 45mg [Reference Formulation, Takeda Pharmaceuticals America, Inc.] in Healthy Human Volunteers Under Fed Conditions.
Lead sponsor
Torrent Pharmaceuticals Limited
Phase
Phase 1
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy